## Background: Luteinizing hormone-releasing hormone agonists (lhrh-a) have become an established treatment for certain patients with prostate carcinoma. lhrh-a are known to decrease bone mineral density. the purpose of this study was to determine the risk of bone fracture in men receiving lhrh-a f
Low bone mineral density in hormone-naïve men with prostate carcinoma
✍ Scribed by Matthew R. Smith; Francis J. McGovern; Mary Anne Fallon; David Schoenfeld; Philip W. Kantoff; Joel S. Finkelstein
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 128 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Sickle cell disease (SCD) is a prevalent genetic disorder in which sickle hemoglobin leads to tissue hypoxia and adverse effects on bone. Published studies suggest that children with SCD often have undiagnosed osteopenia or osteoporosis. Minimal data exist on the prevalence of low bone
## BACKGROUND. Androgen receptor blocking agents have become an established form of therapy for men with disseminated prostate carcinoma. The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities (BMD) in men with disseminated prostate carcinoma treat
## Abstract ## Objective To determine the association between race/ethnicity and bone mineral density (BMD) in women with systemic lupus erythematosus (SLE). ## Methods Women with SLE (n = 298), including 77 African Americans and 221 whites, completed this cross‐sectional study conducted from 19
The volume of the transition zone was also measured by TRUS in 134 patients.